Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians

Neurodegener Dis Manag. 2014;4(3):271-82. doi: 10.2217/nmt.14.17.

Abstract

Apomorphine was introduced before the era of levodopa as a treatment for idiopathic Parkinson's disease (iPD). A number of practical obstacles were to be solved before a wider use of the drug was possible. Today, however, the drug is probably still underutilized. Apomorphine is a strong nonergoline D1 and D2 receptor agonist with a dopaminergic effect comparable with levodopa. In this review motor and non-motor indications for intermittent injections and subcutaneous apomorphine infusions are listed. The reduction of 'off' periods is more than 50% on infusion therapy and if monotherapy is achieved a significant reduction of pre-existing levodopainduced dyskinesias is seen. The aim of this review is to give practical insight into apomorphine treatment, highlighting side effects, and complications and device-related problems are discussed with advice on how to prevent or handle these, should they occur. A number of practical points including the apomorphine test, requirements of the clinical setting, how to increase adherence and troubleshooting are added.

Keywords: apomorphine infusion; apomorphine injection; apomorphine test; dystonia; hyperkinesias; impulse control disorder; motor fluctuations; motor symptoms; non-motor symptoms; rescue medication.

Publication types

  • Review

MeSH terms

  • Antiparkinson Agents / administration & dosage*
  • Antiparkinson Agents / adverse effects
  • Antiparkinson Agents / pharmacokinetics
  • Apomorphine / administration & dosage*
  • Apomorphine / adverse effects
  • Apomorphine / pharmacokinetics
  • Clinical Trials as Topic
  • Drug Delivery Systems / adverse effects
  • Drug Delivery Systems / methods
  • Humans
  • Parkinson Disease / drug therapy*

Substances

  • Antiparkinson Agents
  • Apomorphine